{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:37Z","timestamp":1786979617191,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00108-026-02136-y","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:06:27Z","timestamp":1781006787000},"page":"709-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolische Knochenerkrankungen\u00a0\u2013 was der Internist nicht \u00fcbersehen darf","Metabolic bone disorders: what the internist must not overlook"],"prefix":"10.1007","volume":"67","author":[{"given":"Heide","family":"Siggelkow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2136_CR1","first-page":"297","volume":"121","author":"C Gooch","year":"2024","unstructured":"Gooch\u00a0C, Ekert\u00a0P, Gottesman\u00a0GS (2024) Metabolic Bone Disease: An Overview. Mo Med 121:297\u2013303","journal-title":"Mo Med"},{"key":"2136_CR2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1055\/a-2127-2927","volume":"149","author":"H Siggelkow","year":"2024","unstructured":"Siggelkow\u00a0H, Thomasius\u00a0F (2024) Osteoporosis - implications of the new guidelines in practice. Dtsch Med Wochenschr 149:684\u2013689","journal-title":"Dtsch Med Wochenschr"},{"key":"2136_CR3","first-page":"541","volume":"53","author":"M Drey","year":"2024","unstructured":"Drey\u00a0M, Otto\u00a0S, Thomasius\u00a0F, Schmidmaier\u00a0R (2024) Update of the S3-guideline on diagnostics, prophylaxis and treatment of osteoporosis. Orthopadie (Heidelb) 53:541\u2013549","journal-title":"Orthopadie (Heidelb)"},{"key":"2136_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling\u00a0PR, Nguyen\u00a0HH, Aleksova\u00a0J, Vincent\u00a0AJ, Wong\u00a0P, Milat\u00a0F (2022) Secondary osteoporosis. Endocr Rev 43:240\u2013313","journal-title":"Endocr Rev"},{"key":"2136_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1210\/jcem-73-3-555","volume":"73","author":"JP Bonjour","year":"1991","unstructured":"Bonjour\u00a0JP, Theintz\u00a0G, Buchs\u00a0B, Slosman\u00a0D, Rizzoli\u00a0R (1991) Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J\u00a0Clin Endocrinol Metab 73:555\u2013563","journal-title":"J Clin Endocrinol Metab"},{"key":"2136_CR6","doi-asserted-by":"publisher","first-page":"e3048","DOI":"10.1210\/clinem\/dgac147","volume":"107","author":"R Oheim","year":"2022","unstructured":"Oheim\u00a0R, Tsourdi\u00a0E, Seefried\u00a0L, Beller\u00a0G, Schubach\u00a0M, Vettorazzi\u00a0E et\u00a0al (2022) Genetic diagnostics in routine osteological assessment of adult low bone mass disorders. J\u00a0Clin Endocrinol Metab 107:e3048\u2013e3057","journal-title":"J Clin Endocrinol Metab"},{"key":"2136_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115911","volume":"147","author":"S Butscheidt","year":"2021","unstructured":"Butscheidt\u00a0S, Tsourdi\u00a0E, Rolvien\u00a0T, Delsmann\u00a0A, St\u00fcrznickel\u00a0J, Barvencik\u00a0F et\u00a0al (2021) Relevant genetic variants are common in women with pregnancy and lactation-associated osteoporosis (PLO) and predispose to more severe clinical manifestations. Bone 147:115911","journal-title":"Bone"},{"key":"2136_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/jbmr.4130","volume":"35","author":"L Seefried","year":"2020","unstructured":"Seefried\u00a0L, Dahir\u00a0K, Petryk\u00a0A, H\u00f6gler\u00a0W, Linglart\u00a0A, Martos-Moreno\u00a0G\u00c1 et\u00a0al (2020) Burden of illness in adults with hypophosphatasia: data from the global hypophosphatasia patient registry. J\u00a0Bone Miner Res 35:2171\u20132178","journal-title":"J Bone Miner Res"},{"key":"2136_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","volume":"98","author":"JL Mill\u00e1n","year":"2016","unstructured":"Mill\u00e1n\u00a0JL, Whyte\u00a0MP (2016) Alkaline phosphatase and hypophosphatasia. Calcif Tissue Int 98:398\u2013416","journal-title":"Calcif Tissue Int"},{"key":"2136_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter\u00a0TO, Imel\u00a0EA, Holm\u00a0IA, Jan de Beur\u00a0SM, Insogna\u00a0KL (2011) A clinician\u2019s guide to X\u2011linked hypophosphatemia. J\u00a0Bone Miner Res 26:1381\u20131388","journal-title":"J Bone Miner Res"},{"key":"2136_CR11","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter\u00a0TO, Whyte\u00a0MP, Imel\u00a0EA, Boot\u00a0AM, H\u00f6gler\u00a0W, Linglart\u00a0A et\u00a0al (2018) Burosumab therapy in children with X\u2011linked hypophosphatemia. N\u00a0Engl J Med 378:1987\u20131998","journal-title":"N Engl J Med"},{"key":"2136_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/nrneph.2010.121","volume":"6","author":"AS Alizadeh Naderi","year":"2010","unstructured":"Alizadeh Naderi\u00a0AS, Reilly\u00a0RF (2010) Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 6:657\u2013665","journal-title":"Nat Rev Nephrol"},{"key":"2136_CR13","doi-asserted-by":"crossref","unstructured":"Clegg SM, Eiel ES, Fine S, Gafni RI, Most MJ (2023) Atypical fragility fractures due to bony or soft tissue phosphaturic mesenchymal tumors: a\u00a0report of two cases. Case Rep Orthop 2023:5614065","DOI":"10.1155\/2023\/5614065"},{"key":"2136_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola\u00a0S, Peacock\u00a0M, Fukumoto\u00a0S, Cipriani\u00a0C, Pepe\u00a0J, Tella\u00a0SH et\u00a0al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044","journal-title":"Nat Rev Dis Primers"},{"key":"2136_CR15","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","volume":"38","author":"JA Glaspy","year":"2021","unstructured":"Glaspy\u00a0JA, Wolf\u00a0M, Strauss\u00a0WE (2021) Intravenous iron-induced hypophosphatemia: an emerging syndrome. Adv Ther 38:3531\u20133549","journal-title":"Adv Ther"},{"key":"2136_CR16","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2169\/internalmedicine.4029-19","volume":"59","author":"R Takase","year":"2020","unstructured":"Takase\u00a0R, Nakano\u00a0Y, Hasegawa\u00a0K, Otsuka\u00a0F (2020) X\u2011linked hypophosphatemia (XLH) mimicking rheumatic disease. Intern Med 59:1233\u20131234","journal-title":"Intern Med"},{"issue":"8","key":"2136_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc0800696","volume":"359","author":"M Cirillo","year":"2008","unstructured":"Cirillo\u00a0M, Ciacci\u00a0C, De Santo\u00a0NG (2008) Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N\u00a0Engl J Med 359(8):864\u2013866","journal-title":"N Engl J Med"},{"key":"2136_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1053\/j.ajkd.2015.06.027","volume":"67","author":"KD Yoo","year":"2016","unstructured":"Yoo\u00a0KD, Kang\u00a0S, Choi\u00a0Y, Yang\u00a0SH, Heo\u00a0NJ, Chin\u00a0HJ et\u00a0al (2016) Sex, age, and the association of serum phosphorus with all-cause mortality in adults with normal kidney function. Am J Kidney Dis 67:79\u201388","journal-title":"Am J Kidney Dis"},{"key":"2136_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","volume":"21","author":"S Khan","year":"2025","unstructured":"Khan\u00a0S, Khan\u00a0AA (2025) Hypoparathyroidism: diagnosis, management and emerging therapies. Nat Rev Endocrinol 21:360\u2013374","journal-title":"Nat Rev Endocrinol"},{"key":"2136_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40618-024-02496-y","volume":"48","author":"T De Coster","year":"2020","unstructured":"De Coster\u00a0T, David\u00a0K, Breckpot\u00a0J, Decallonne\u00a0B (2020) Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations. J\u00a0Endocrinol Invest 48:831\u2013844","journal-title":"J Endocrinol Invest"},{"key":"2136_CR21","volume":"16","author":"M Kothari","year":"2024","unstructured":"Kothari\u00a0M, Wanjari\u00a0A, Shaikh\u00a0SM, Tantia\u00a0P, Waghmare\u00a0BV, Parepalli\u00a0A et\u00a0al (2024) A\u00a0Comprehensive review on understanding magnesium disorders: pathophysiology, clinical manifestations, and management strategies. Cureus 16:e68385","journal-title":"Cureus"},{"issue":"1","key":"2136_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-06045-5","volume":"46","author":"OD Lotkowska","year":"2025","unstructured":"Lotkowska\u00a0OD, Adler\u00a0S, Zgraggen\u00a0A (2025) Methotrexate osteopathy in rheumatoid arthritis. Rheumatol Int 46(1):8","journal-title":"Rheumatol Int"},{"key":"2136_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00223-024-01290-5","volume":"115","author":"FN von Brackel","year":"2024","unstructured":"von Brackel\u00a0FN, Grambeck\u00a0J, Barvencik\u00a0F, Amling\u00a0M, Oheim\u00a0R (2024) MTX osteopathy versus osteoporosis including response to treatment data\u2011a retrospective single center study including 172 patients. Calcif Tissue Int 115:599\u2013610","journal-title":"Calcif Tissue Int"},{"key":"2136_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1055\/a-1241-6555","volume":"147","author":"KSC Gollisch","year":"2022","unstructured":"Gollisch\u00a0KSC, Siggelkow\u00a0H (2022) Primary hyperparathyreoidism - diagnostic procedures and management. Dtsch Med Wochenschr 147:187\u2013199","journal-title":"Dtsch Med Wochenschr"},{"key":"2136_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162637","volume":"17","author":"M Daraghma","year":"2025","unstructured":"Daraghma\u00a0M, Aswani\u00a0Y, Jain\u00a0S, Laudicella\u00a0R, Gholamrezanezhad\u00a0A, Menda\u00a0Y et\u00a0al (2025) PET\/CT and paraneoplastic syndromes: a comprehensive review. Cancers (Basel) 17:2637","journal-title":"Cancers (Basel)"},{"key":"2136_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1055\/a-2175-9246","volume":"32","author":"C Grasemann","year":"2023","unstructured":"Grasemann\u00a0C, Baverncik\u00a0F, Siggelkow\u00a0H, Kocijan\u00a0R, Tsourdi\u00a0E, H\u00f6gler\u00a0W et\u00a0al (2023) Praxisrelevante Aspekte zur biochemischen und molekulargenetischen Diagnostik bei seltenen Knochenerkrankungen \u2013 vom Netzwerk Seltene Osteopathien (NetsOs*). Osteologie 32:270\u2013277","journal-title":"Osteologie"},{"key":"2136_CR27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/bcp.13803","volume":"85","author":"FM Hannan","year":"2019","unstructured":"Hannan\u00a0FM, Newey\u00a0PJ, Whyte\u00a0MP, Thakker\u00a0RV (2019) Genetic approaches to metabolic bone diseases. Br J Clin Pharmacol 85:1147\u20131160","journal-title":"Br J Clin Pharmacol"},{"key":"2136_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01441-z","volume":"19","author":"B Cortet","year":"2024","unstructured":"Cortet\u00a0B, Gua\u00f1abens\u00a0N, Brandi\u00a0ML, Siggelkow\u00a0H (2024) Similarities and differences between European guidelines for the management of postmenopausal osteoporosis. Arch Osteoporos 19:84","journal-title":"Arch Osteoporos"},{"key":"2136_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1358\/dot.2016.52.5.2482878","volume":"52","author":"C Hofmann","year":"2015","unstructured":"Hofmann\u00a0C, Seefried\u00a0L, Jakob\u00a0F (2015) Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc) 52:271\u2013285","journal-title":"Drugs Today (Barc)"},{"key":"2136_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","volume":"78","author":"YN Lamb","year":"2018","unstructured":"Lamb\u00a0YN (2018) Burosumab: first global approval. Drugs 78:707\u2013714","journal-title":"Drugs"},{"key":"2136_CR31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1056\/NEJMc2302708","volume":"389","author":"RI Gafni","year":"2023","unstructured":"Gafni\u00a0RI, Hartley\u00a0IR, Roszko\u00a0KL, Nemeth\u00a0EF, Pozo\u00a0KA, Lombardi\u00a0E et\u00a0al (2023) Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1. N\u00a0Engl J Med 389:1245\u20131247","journal-title":"N Engl J Med"},{"key":"2136_CR32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","volume":"39","author":"FH Glorieux","year":"2024","unstructured":"Glorieux\u00a0FH, Langdahl\u00a0B, Chapurlat\u00a0R, De Beur\u00a0SJ, Sutton\u00a0VR, Poole\u00a0KES et\u00a0al (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. J\u00a0Bone Miner Res 39:1215\u20131228","journal-title":"J Bone Miner Res"},{"key":"2136_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-025-01356-y","volume":"116","author":"L Seefried","year":"2025","unstructured":"Seefried\u00a0L, Genest\u00a0F, Hofmann\u00a0C, Brandi\u00a0ML, Rush\u00a0E (2025) Diagnosis and treatment of hypophosphatasia. Calcif Tissue Int 116:46","journal-title":"Calcif Tissue Int"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02136-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02136-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02136-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T12:28:09Z","timestamp":1782736089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02136-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02136-y","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Siggelkow war innerhalb der letzten drei Jahre Mitglied eines Advisory Boards f\u00fcr Ascendis, BridgeBio, UCB und Kyowa Kirin und hat Vortragshonorare von Ascendis, BridgeBio, UCB, Kyowa Kirin, Sandoz Hexal, Merck\/Serono und Amgen erhalten. H.\u00a0Siggelkow ist Mitglied im Netzwerk f\u00fcr seltene Osteopathien (NetsOs), im Vorstand der Deutschen Gesellschaft f\u00fcr Osteologie, im Beirat der Deutschen Gesellschaft f\u00fcr Endokrinologie (DGE), im Vorstand der European Calcified Tissue Society (ECTS) und Chair des Communication Committee der ECTS und weiterhin in der Arbeitsgruppe f\u00fcr Seltene Knochenerkrankungen der European Society of Endocrinology (ESE). E.\u00a0Tsourdi war innerhalb der letzten drei Jahre Mitglied eines Advisory Boards f\u00fcr UCB und Ascendis Pharma und hat Vortragshonorare von Ascendis Pharma, UCB und Amgen erhalten. E.\u00a0Tsourdi ist Mitglied im Netzwerk f\u00fcr seltene Knochenerkrankungen (NetsOs), Beiratsmitglied der Deutschen Gesellschaft f\u00fcr Endokrinologie (DGE), Beiratsmitglied der Arbeitsgruppe Education der European Calcified Tissue Society (ECTS) und Co-Chair des Programms Rare-CaPaB der European Society of Endocrinology (ESE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}